Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - OtherShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Usana Health Sciences (USNA) Shares Outstanding (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Shares Outstanding for 17 consecutive years, with $18.3 million as the latest value for Q1 2026.

  • Quarterly Shares Outstanding fell 4.11% to $18.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $18.3 million through Jan 2026, down 4.11% year-over-year, with the annual reading at $18.3 million for FY2026, 4.11% down from the prior year.
  • Shares Outstanding for Q1 2026 was $18.3 million at Usana Health Sciences, roughly flat from $18.3 million in the prior quarter.
  • The five-year high for Shares Outstanding was $19.4 million in Q1 2022, with the low at $18.3 million in Q2 2025.
  • Average Shares Outstanding over 5 years is $19.0 million, with a median of $19.1 million recorded in 2023.
  • The sharpest move saw Shares Outstanding fell 7.82% in 2022, then grew 0.57% in 2023.
  • Over 5 years, Shares Outstanding stood at $19.2 million in 2022, then decreased by 0.4% to $19.1 million in 2023, then fell by 0.35% to $19.1 million in 2024, then fell by 4.15% to $18.3 million in 2025, then grew by 0.05% to $18.3 million in 2026.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $18.3 million, $18.3 million, and $18.3 million for Q1 2026, Q3 2025, and Q2 2025 respectively.